Novo Nordisk A/S $NVO Stock Holdings Lifted by Princeton Global Asset Management LLC

Princeton Global Asset Management LLC raised its stake in Novo Nordisk A/S (NYSE:NVO) by 6.4% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 4,520 shares of the company’s stock after buying an additional 270 shares during the period. Princeton Global Asset Management LLC’s holdings in Novo Nordisk A/S were worth $312,000 as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. Copeland Capital Management LLC increased its holdings in shares of Novo Nordisk A/S by 184.8% in the first quarter. Copeland Capital Management LLC now owns 393 shares of the company’s stock valued at $27,000 after buying an additional 255 shares in the last quarter. North Capital Inc. bought a new position in shares of Novo Nordisk A/S in the first quarter valued at $27,000. Stone House Investment Management LLC bought a new position in shares of Novo Nordisk A/S in the first quarter valued at $30,000. Disciplina Capital Management LLC increased its holdings in shares of Novo Nordisk A/S by 162.3% in the first quarter. Disciplina Capital Management LLC now owns 480 shares of the company’s stock valued at $33,000 after buying an additional 297 shares in the last quarter. Finally, Dagco Inc. bought a new position in shares of Novo Nordisk A/S in the first quarter valued at $35,000. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Price Performance

Shares of NYSE:NVO opened at $55.78 on Tuesday. The company has a current ratio of 0.78, a quick ratio of 0.56 and a debt-to-equity ratio of 0.52. Novo Nordisk A/S has a 1 year low of $45.05 and a 1 year high of $117.96. The business has a fifty day simple moving average of $56.36 and a 200 day simple moving average of $62.64. The firm has a market cap of $249.04 billion, a price-to-earnings ratio of 15.32, a P/E/G ratio of 2.50 and a beta of 0.68.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Wednesday, August 6th. The company reported $0.97 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.93 by $0.04. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%.The business had revenue of $11.69 billion during the quarter, compared to analyst estimates of $77.51 billion. As a group, sell-side analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The firm also recently announced a semi-annual dividend, which was paid on Tuesday, August 26th. Shareholders of record on Monday, August 18th were given a dividend of $0.4119 per share. This represents a yield of 240.0%. The ex-dividend date of this dividend was Monday, August 18th. Novo Nordisk A/S’s dividend payout ratio is presently 22.53%.

Analysts Set New Price Targets

Several brokerages have issued reports on NVO. Zacks Research raised shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research note on Monday, September 29th. Berenberg Bank raised shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Wednesday, September 17th. HSBC set a $70.00 target price on shares of Novo Nordisk A/S in a research note on Wednesday, October 1st. BNP Paribas Exane raised shares of Novo Nordisk A/S from an “underperform” rating to a “neutral” rating and set a $54.00 target price on the stock in a research note on Wednesday, August 13th. Finally, BNP Paribas raised shares of Novo Nordisk A/S from an “underperform” rating to a “neutral” rating in a research note on Wednesday, August 13th. Two research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $76.00.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.